• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Gilead Sciences (NQ: GILD )

    68.61 UNCHANGED
    Streaming Delayed Price Updated: 4:00 PM EDT, Jun 28, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 5,297
    Open 68.61
    Bid (Size) 68.66 (1)
    Ask (Size) 68.95 (1)
    Prev. Close 68.61
    Today's Range 68.61 - 68.61
    52wk Range 62.07 - 87.86
    Shares Outstanding 1,253,809,440
    Dividend Yield 4.37%
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    3 Magnificent Stocks Retirees Can Buy and Hold Forever
    These stocks could be ideal for investors in their golden years. 
    Via The Motley Fool
    Wall Street's Most Accurate Analysts Give Their Take On 3 Health Care Stocks With Over 3% Dividend Yields
    Via Benzinga

    Performance

    YTD
    -17.58%
    -17.58%
    1 Month
    +6.75%
    +6.75%
    3 Month
    -5.86%
    -5.86%
    6 Month
    -17.58%
    -17.58%
    1 Year
    -10.57%
    -10.57%

    More News

    Read More
    10 Health Care Stocks Whale Activity In Today's Session
    Via Benzinga
    Gilead Sciences's Options Frenzy: What You Need to Know
    Via Benzinga
    7 Dividend Stocks to Buy Now: June 2024
    Via InvestorPlace
    $100 Invested In This Stock 20 Years Ago Would Be Worth $800 Today
    Via Benzinga
    DraftKings And Dell Were Among The 10 Biggest Large Cap Stock Gainers Last Week (June 16-June 22): Are These In Your Portfolio?
    Via Benzinga
    MarketBeat Week in Review – 6/17 - 6/21
    Via MarketBeat
    Topics Economy Stocks
    Exposures Interest Rates US Equities
    Top Analyst Reports For Abbott, BP & Gilead
    Via Talk Markets
    Nvidia Snaps 8-Week Winning Run, S&P 500 Marks Longest Streak Without A 2% Drop Since Great Recession, Oil Prices Stage Comeback: This Week In The Market
    Via Benzinga
    Topics Economy Stocks
    Exposures Economy US Equities
    Gilead Sciences Faces Wall Street Speculation About Obesity Drugs Despite Focus On Liver Treatments
    Via Benzinga
    Why Gilead Sciences Stock Is Trading Higher Friday
    Via Benzinga
    Pre-Market Movers - June 21, 2024
    Via Talk Markets
    Gilead Sciences Stock Surges on HIV Treatment Trial Success
    Via MarketBeat
    Exposures Product Safety
    Defying the Norms: 3 High P/E Stocks With Room to Run
    Via InvestorPlace
    S&P 500, Nasdaq 100 Dip From Record Highs As Investors Take Chipmaker Profits; Energy Sector Rebounds, Yields Rise: What's Driving Markets Thursday?
    Via Benzinga
    Topics Stocks
    Exposures US Equities
    Gilead Flashes A Bullish Sign After HIV Drug Proves 100% Effective
    Via Investor's Business Daily
    Why Is Gilead Sciences Stock Trading Higher On Thursday?
    Via Benzinga
    KB Home Reports Upbeat Earnings, Joins Harrow, Accenture, Gilead Sciences And Other Big Stocks Moving Higher On Thursday
    Via Benzinga
    Gilead’s Twice-Yearly Lenacapavir Demonstrated 100% Efficacy and Superiority to Daily Truvada® for HIV Prevention
    From Gilead Sciences, Inc.
    Via Business Wire
    Biotechs Race to Develop New Treatments as Global Pancreatic Cancer Market Size Expected to Reach $7.5 Billion by 2033
    Via FinancialNewsMedia
    Biotechs Race to Develop New Treatments as Global Pancreatic Cancer Market Size Expected to Reach $7.5 Billion by 2033
    From FN Media Group LLC
    Via GlobeNewswire
    7 Breakthrough Biotech Stocks for a Shot of Portfolio Adrenaline
    Via InvestorPlace
    Gilead Has A Narrative-Changing Revelation For Its Weight-Loss Contender
    Via Investor's Business Daily
    Detailed Data From Gilead Halted Blood Cancer Drug Magrolimab Program Shows Higher Deaths And Side Effects
    Via Benzinga
    Topics Death
    Exposures Death
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.